Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs. Standard of Care in Relapsed and Refractory Multiple Myeloma in Phase 3...
Business Wire•08/10/2026•06:59 ET
3
Key Highlights
- ➤ZENBEXUS ZDd median PFS 42 months versus 20 months for standard care
- ➤ZDd reduced disease progression or death risk 51%, with HR 0.49
- ➤EXCALIBER-RRMM enrolled 800 patients randomized evenly between ZDd and DVd
- ➤ZENBEXUS indication remains accelerated approval, contingent on confirmatory clinical benefit
Expert Statements
Cristian Massacesi, Chief medical officer and head of development at Bristol Myers Squibb
“The results from EXCALIBER-RRMM reinforce the clinical value of ZENBEXUS in combination with daratumumab and dexamethasone as a treatment approach for relapsed or refractory multiple myeloma, demonstrating the strong benefit observed for minimal residual disease negativity translated to a meaningful improvement in progression free survival for patients”
Cristian Massacesi, Chief medical officer and head of development at Bristol Myers Squibb
“These findings further underscore the value of ZENBEXUS as an effective oral treatment option that can be easily used in diverse care settings, including community settings, where many patients receive their care.”
Bristol Myers Squibb Announces ZENBEXUS(TM) (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs. Standard of Care in Relapsed and Refractory Multiple Myeloma in Phase 3...
In the EXCALIBER study, results showed a progression-free survival hazard ratio of 0.49 compared with daratumumab, bortezomib and dexamethasone
Get started
Create a free account to read the full story.